ClinicalTrials.gg
RecruitingNCT05519449Updated Oct 29, 2026

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

A Phase 1 interventional study of JANX007 and Darolutamide in Prostate Cancer, Metastatic Castration-resistant Prostate Cancer and Castration Resistant Prostatic Cancer, sponsored by Janux Therapeutics. Recruiting at 38 sites in 3 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionProstatic Neoplasms, Castration-ResistantRegistry: Prostatic NeoplasmsReclassifiedWhy we changed it
Registry
Prostatic Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prostatic Neoplasms, Castration-Resistant
Why
  1. The study's listed conditions name Prostatic Neoplasms, Castration-Resistant, a narrower term within Prostatic Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Janux Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.
Updated Oct 29, 2026First site in Spain2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
272
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 17 open to participants now, 23 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Planned enrollment
9th of 42
272 · median 91
Started
2022
with 5 others
Phase 1
15 of 50
5 open now
Primary completion
2027-07
later than 8 of 22 live
Registered
29th of 50
by date

Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 9th largest by planned enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2022, is one of 15 in phase 1, reaches primary completion later than 8 of the 22 other live ones, and was the 29th registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

17 of the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

03

Conditions studied

  • Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Castration Resistant Prostatic Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Castration-resistant prostate cancer
04

In context

Prostatic Neoplasms, Castration-Resistant Reclassified

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

This study's planned enrollment of 272 is above the median of 82 across 62 interventional studies indexed under Prostatic Neoplasms, Castration-Resistant.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Lead sponsor

Janux Therapeutics is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Compared within Prostatic Neoplasms, Castration-Resistant, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Prostatic Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male ≥18 years of age at the time of signing
  • or cytologically confirmed adenocarcinoma of the prostate
  • For Dose Escalation and Backfill: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible
  • Adequate organ function
  • For Monotherapy Expansion Part a: Have received ≤ 2 anti-androgen therapies in either the HSPC or CRPC setting and no more than 1 prior taxane regimen in the HSPC or CRPC setting. Participants who have actively refused a taxane regimen or are medically unsuitable to receive taxane are eligible.
  • For Monotherapy Expansion Part b: Have received ≤ 2 anti-androgen therapies in either the HSPC or CRPC settings
  • For Monotherapy Expansion Part d: Have received ≤ 1 anti-androgen therapy and a poly(ADP-ribose) polymerase (PARP) inhibitor for mCRPC and have progressed following treatment with the PARP inhibitor
  • For Combination Expansion: Have received ≤ 1 anti-androgen therapy other than darolutamide in the HSPC setting and ≤ 1 taxane in the mCRPC setting. Participants who have actively refused a taxane regimen or are medically unsuitable to receive taxane are eligible.

Exclusion criteria

Exclusion Criteria:

  • Prior solid organ transplant
  • Prior treatment with PSMA-targeted CAR-T cell therapy or PSMA-CD3, PSMA-CD28 or other CD3 T-cell engaging bispecific antibodies or radioligand therapy
  • cardiovascular disease
  • For Monotherapy Expansion Part a: Prior receipt of any treatment other than an ARPI or taxane in the mCRPC setting
  • For Monotherapy Expansion Part b: Prior receipt of any treatment other than an anti-androgen therapy or prior receipt of a taxane containing regimen or more than 1 for mCRPC
  • For Monotherapy Part d: More than 1 prior line of therapy for mCRPC or prior receipt of any treatment other than an anti-androgen therapy and PARP inhibitor for mCRPC or prior receipt of a taxane in the mCRPC setting
  • For Combination expansion: More than 1 prior line of therapy for mCRPC or prior receipt of any treatment other than a taxane for mCRPC or prior receipt of Darolutamide or prior receipt of a taxane for HSPC
  • Active clinically significant infection (bacterial, viral, fungal, mycobacteria or other)
  • Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
272 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    IV dosing during 21- or 28-day cycles. Dosage per cohort will increase to determine the maximum tolerable dose.

    Biological: JANX007

  • Experimental
    Backfill Expansion

    IV dosing during 21- or 28-day cycles. Subjects will be dosed at levels previously declared tolerable.

    Biological: JANX007

  • Experimental
    Monotherapy Expansion Parts A - D

    IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose (RP2D).

    Biological: JANX007

  • Experimental
    Combination Expansion

    IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose

    Biological: JANX007 · Drug: Darolutamide

Interventions

  • BiologicalJANX007

    JANX007 is dosed via IV in a 21- or 28-day cycle.

  • Darolutamide is dosed via oral tablets

07

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLT)

    Time frame: 3 years

  2. Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)

    Time frame: 3 years

Secondary outcomes

  1. Area under the concentration time curve to infinity of JANX007 (AUC0-inf)

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1, 2, 4, 8, 9, 15, 16, 18 up to end of treatment (Up to 3 years)

  2. Maximum observed concentration of JANX007 (Cmax)

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1, 2, 4, 8, 9, 15, 16, 18 up to end of treatment (Up to 3 years)

  3. Number of participants who develop anti-drug antibodies against JANX007

    Time frame: Up to 3 years

  4. Duration of Response

    Time from documentation of complete response or partial response to disease progression using RECIST v1.1 and PCWG3

    Time frame: Up to 3 years

  5. Prostate Specific Antigen (PSA) response

    Best reduction in PSA level achieved confirmed by a second PSA test ≥21 days later

    Time frame: Up to 3 years

  6. Radiographic Progression Free Survival (rPFS)

    Time from treatment initiation to radiographic evidence of disease progression using RECIST v1.1 and PCWG3

    Time frame: Up to 3 years

  7. Overall Response Rate

    Proportion of participants who achieve a complete response or partial response using RECIST v1.1 and PCWG3

    Time frame: Up to 3 years

  8. Overall Survival

    Time from treatment initiation until death from any cause

    Time frame: Up to 3 years

08

Study locations

38 of 38 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jul 2027, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Aug 29, 2022
StartActual
Sep 15, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Spain
Show 2 added (2 Spain)
  • Start Madrid - FJD, Hospital Fundacion Jimenez Diaz · Madrid, Spain
  • START Madrid / Centro Integral Oncologico Clara Campal · Madrid, Spain
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    2 sites added — first site in Spain
    Show 2 added (2 Spain)
    • Start Madrid - FJD, Hospital Fundacion Jimenez Diaz · Madrid, Spain
    • START Madrid / Centro Integral Oncologico Clara Campal · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05519449
Lead sponsor
Janux Therapeutics
Responsible party
Sponsor
First posted
Aug 29, 2022
Start date
Sep 15, 2022
Primary completion
Jul 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Janux Therapeutics
Contact
psma-007-001_ct.gov@januxrx.com
858-206-8471
Janux Therapeutics, MD
study director · Janux Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion